Three months into the COVID-19 outbreak caused by a novel strain of coronavirus (SARS-CoV-2), the world is still in search of an effective therapeutic drug. Experimental drugs developed for other infections, such as Gilead's remdesivir, have been repurposed with unclear success. A recent small...

The Covid-19 pandemic is estimated to have caused over 7 million deaths and reduced economic output by over $13 trillion to date. While vaccines were developed and deployed with unprecedented speed, pre-pandemic investments could have accelerated their widespread introduction, saving millions of...

We derive the optimal funding mechanism to incentivize development and production of vaccines against diseases with epidemic potential. In the model, suppliers' costs are private information and investments are noncontractible, precluding cost-reimbursement contracts, requiring fixed-price...

Since 2021, vaccinations for Coronavirus Disease 2019 (COVID-19) are more and more a health policy to cope with on-going pandemic crisis. Is this policy response enough to stop the diffusion of novel coronavirus and reduce the negative impact in society? The goal of this study here is to...

The Covid-19 pandemic tragically emphasized severe failures of health systems. In particular, the saturation of hospital infrastructures and the lack of medical devices is crucial for respiratory ventilators. The medical and pharmaceutical sectors had to find urgently new ways to innovate...

Using recent data on the unvaccinated across U.S. states, this paper focuses on the determinants of vaccine hesitancy related to the COVID-19 pandemic. Results show that more prosperous states and states with more elderly and physicians have lower vaccine hesitancy. There was some evidence of...

Without a vaccine for COVID-19, the pandemic will be here for some time. Measures such as social distancing and robust surveillance can control the spread of the disease, but there will always be a risk that a flare-up will take lives, especially those of elderly and immunocompromised...

This working paper provides a statistical analysis of 74 patent families which cover subject matter relevant to ten COVID-19 vaccines. These vaccines have accounted for 99% of the global COVID-19 vaccine production as of 31 December 2021, comprising over ten billion doses. Eight of them, namely...

The emergence of Covid-19 has affected all aspects of human life across the globe. Lockdowns everywhere are having dramatic social and economic consequences. No therapy has yet been approved, and vaccines are a priority potential tool to control the pandemic and its impacts. Multiple vaccines...

In this study, we use random assignment of vignettes that feature optimistic and pessimistic scenarios with respect to vaccine safety and efficacy on a sample of roughly 1,600 Russians in order to gauge public support for anti-pandemic measures under various scenarios. Negative information on...